Alcohol dependence and liver disease – when extended medical evaluation is needed
The liver is the organ that first bears the consequences of alcohol misuse and the last to give clear signs of damage. This apparent paradox stems from its exceptional capacity for regeneration and compensation – a liver being damaged over time causes no distinct symptoms for a long while. When symptoms finally appear, the changes are usually advanced. For people with alcohol dependence and for the clinicians treating them, this means one thing: you cannot wait for symptoms. Extended medical evaluation of the liver is indicated early and regardless of how the patient feels.
Alcohol and the liver – mechanisms of damage
The liver is the primary site of ethanol metabolism. The enzyme alcohol dehydrogenase (ADH) converts ethanol into acetaldehyde – a substance more toxic than alcohol itself – which is then broken down to acetate by aldehyde dehydrogenase (ALDH). With intensive or prolonged drinking, these enzymatic pathways become overloaded and acetaldehyde accumulates in liver tissue, causing direct cellular damage.
Simultaneously, alcohol activates the microsomal ethanol oxidising system (MEOS) involving cytochrome CYP2E1, which generates reactive oxygen species and amplifies oxidative stress. This leads to lipid peroxidation, mitochondrial damage and induction of hepatocyte apoptosis. Chronic drinking also activates Kupffer cells – resident hepatic macrophages – which intensify the inflammatory response by releasing pro-inflammatory cytokines, including TNF-alpha.
The result of these processes is the spectrum of alcoholic liver disease (ALD): from fatty liver through alcoholic hepatitis to cirrhosis. Importantly, these stages can coexist and do not always follow each other sequentially.
The spectrum of alcoholic liver disease
Alcoholic fatty liver (alcoholic steatosis)
Fatty liver is the earliest and most common form of alcoholic liver disease – it is estimated to develop in over 90% of people who chronically drink more than 60 g of ethanol daily (equivalent to approximately 6 standard drinks). It consists of the accumulation of triglycerides inside hepatocytes, which disrupts their normal function.
In the typical course, fatty liver causes no symptoms or only non-specific discomfort in the right upper quadrant and fatigue. Laboratory tests may be normal or show moderate GGT elevation. Ultrasound reveals the characteristic image of a “bright liver” – hyperechoic and enlarged. The good news: alcoholic fatty liver is fully reversible after stopping drinking – clinical studies document normalisation of the ultrasound image within a few weeks of abstinence.
Alcoholic hepatitis (AH)
Alcoholic hepatitis is a more serious condition – an acute inflammatory syndrome with hepatocyte necrosis that can develop on the basis of pre-existing liver disease or de novo. Severe alcoholic hepatitis (defined as Maddrey discriminant function DF ≥32 or MELD ≥20) is associated with short-term mortality reaching 30-50% within 28 days without treatment.
Clinically, severe AH presents with sudden onset of jaundice, abdominal pain, fever, leucocytosis and significant deterioration of liver function. For the physician treating the addiction, it is crucial to recognise that a patient in this condition requires hepatological evaluation and hospitalisation above all – not outpatient detoxification.
Liver cirrhosis
Alcoholic cirrhosis is the irreversible stage of the disease – liver tissue is replaced by fibrous tissue and the architecture of the organ is permanently destroyed. It is estimated that cirrhosis develops in 10-20% of people who drink heavily for many years. Risk factors include: female sex (women are more susceptible at lower doses), genetic predisposition, concurrent infection with hepatotropic viruses and obesity.
Compensated cirrhosis (without complications) can be asymptomatic for many years. Decompensation manifests as ascites, hepatic encephalopathy, oesophageal varices and spontaneous bacterial peritonitis. Five-year survival for compensated cirrhosis is approximately 80-85%; for decompensated cirrhosis it falls to 35-50%.
When extended hepatological evaluation is required
Standard qualification for alcohol detoxification includes a full blood count, liver tests (AST, ALT, GGT, bilirubin), creatinine, electrolytes and INR. These are screening investigations – and for some patients they are sufficient. However, a range of clinical situations call for deeper hepatological assessment.
How liver disease affects addiction treatment
Liver diseases are not merely a “clinical backdrop” to addiction treatment – they actively affect its safety and efficacy.
The liver metabolises most drugs used during alcohol detoxification – benzodiazepines, thiamine, symptomatic medications. With impaired liver function, the metabolism of these drugs is slowed and their blood concentrations can reach toxic levels at standard doses. This is particularly important for benzodiazepines – the first-line drugs for treating withdrawal syndrome – which are entirely metabolised by the liver.
Hepatic encephalopathy – disturbances of consciousness and cognitive function resulting from accumulation of toxins not filtered by the diseased liver – can complicate differentiation from alcohol withdrawal delirium. Clinical distinction between these conditions is of crucial therapeutic significance.
Liver cirrhosis with portal hypertension also changes the risk profile of procedures and medications. Oesophageal varices are at risk of bleeding, particularly with the tachycardia accompanying acute withdrawal syndrome. Coagulation disorders increase the risk of haemorrhagic complications.
Hepatological assessment and addiction treatment planning
The results of hepatological assessment directly influence the planning of alcohol detoxification. A patient with compensated cirrhosis without complications can undergo detoxification in a detoxification clinic – with appropriate adjustment of pharmacotherapy and close monitoring. A patient with severe alcoholic hepatitis or decompensated cirrhosis requires hospitalisation in a hepatology or gastroenterology unit with intensive care facilities.
Knowledge of liver status also matters for long-term addiction treatment planning. Pharmacotherapy maintaining abstinence – naltrexone, acamprosate – must be used cautiously with impaired liver function. Disulfiram (used as a subcutaneous implant) is hepatotoxic and is contraindicated with active hepatitis or advanced cirrhosis.
Patients with advanced cirrhosis are sometimes referred by their hepatologist to transplant centres for qualification assessment. Alcohol abstinence is one of the key conditions for this qualification – and its documentation by an addiction treatment centre is required by transplant committees as evidence of sustained change. We assist patients in obtaining such documentation and work closely with the treating hepatologist.
When contact with a hepatologist is urgent
Not every hepatological consultation in a person with alcohol dependence is urgent – but some situations require a rapid response.
Hepatological consultation – what to know
A hepatological consultation in a person with alcohol dependence includes a history of drinking and previous treatment, physical examination assessing signs of liver disease, analysis of available laboratory and imaging results, and a diagnostic and therapeutic plan. Depending on the situation, it may include liver elastography (FibroScan) – a non-invasive method of fibrosis assessment – Doppler ultrasound of vessels, and in selected cases liver biopsy.
It is important that hepatological consultation complements rather than replaces addiction treatment. The best prognosis is for patients who simultaneously undertake comprehensive alcohol treatment and regular hepatological care – because abstinence is the most powerful available treatment for alcoholic liver disease, while addiction is a disease requiring specialised therapy. Addiction therapy undertaken in parallel with hepatological treatment gives the patient the best chance both of sobriety and of halting the progression of liver disease.
Frequently asked questions
When should a person with alcohol dependence have liver tests done?
Liver tests are indicated for every person with dependence or heavy drinking lasting more than a few months. Urgent evaluation is indicated with jaundice, right upper quadrant pain, ascites, oedema or weakness disproportionate to abstinence duration. They are standard as part of detox qualification.
Which liver enzymes are elevated with alcohol misuse?
Most commonly GGT – a very sensitive marker, AST and ALT – indicators of cell damage. AST/ALT ratio above 2 is characteristic of alcoholic liver disease. Elevated bilirubin and low albumin indicate synthetic function impairment – a more serious signal.
Is liver disease reversible after stopping drinking?
Alcoholic fatty liver is fully reversible. Alcoholic hepatitis can resolve with abstinence and treatment. Cirrhosis is irreversible – but progression can be halted and some function may improve. Early evaluation and addiction treatment are therefore crucial.
Can detoxification be undertaken with a damaged liver?
Yes, but it requires modified management – adjusted drug doses and close monitoring. Severe cirrhosis with complications may require hospital-based detoxification. Hepatological evaluation before detox is clinically justified in such cases.
References
- Singal AK, Bataller R, Ahn J, Kamath PS, Shah VH. ACG Clinical Guideline: Alcoholic Liver Disease. Am J Gastroenterol. 2018;113(2):175-194. doi:10.1038/ajg.2017.469
- European Association for the Study of the Liver (EASL). EASL Clinical Practice Guidelines: Alcohol-related liver disease. J Hepatol. 2018;69(1):154-181. doi:10.1016/j.jhep.2018.03.018
- Lucey MR, Mathurin P, Morgan TR. Alcoholic hepatitis. N Engl J Med. 2009;360(26):2758-2769. doi:10.1056/NEJMra0805786
- Crabb DW, Im GY, Szabo G, Mellinger JL, Lucey MR. Diagnosis and Treatment of Alcohol-Associated Liver Diseases: 2019 Practice Guidance From the American Association for the Study of Liver Diseases. Hepatology. 2020;71(1):306-333. doi:10.1002/hep.30866
- Lieber CS. Alcoholic fatty liver: its pathogenesis and mechanism of progression to inflammation and fibrosis. Alcohol. 2004;34(1):9-19. doi:10.1016/j.alcohol.2004.07.008
- Rehm J, Samokhvalov AV, Shield KD. Global burden of alcoholic liver diseases. J Hepatol. 2013;59(1):160-168. doi:10.1016/j.jhep.2013.03.007
- Mandrekar P, Szabo G. Signalling pathways in alcohol-induced liver inflammation. J Hepatol. 2009;50(6):1258-1266. doi:10.1016/j.jhep.2009.03.007
- Reus VI, Fochtmann LJ, Bukstein O, et al. The American Psychiatric Association Practice Guideline for the Pharmacological Treatment of Patients With Alcohol Use Disorder. Am J Psychiatry. 2018;175(1):86-90.
CLINICAL INQUIRY
The form is intended for submitting a clinical inquiry. Messages are delivered directly to the team responsible for treatment coordination.
Related Treatment Areas
Clinical Contact
Contact with the center is intended for providing information regarding inpatient treatment and coordinating next steps in a confidential and non-binding manner.
Scope of Treatment and Informational Nature of Content
Inpatient treatment provided at Zeus Detox & Rehab is clinical in nature and focuses on medical stabilization, psychiatric assessment, and therapeutic intervention appropriate to the diagnosed condition and stage of the disorder. The scope and structure of treatment are determined individually by the clinical team based on the patient’s current health status and applicable medical standards.
The information presented on this website is for educational and informational purposes only. It does not constitute medical advice and should not be used as a basis for self-directed treatment decisions. Addiction and mental health treatment require individual medical qualification and clinical assessment.
